Rigor Reviewed

Rigor-Reviewed Manuscript

A Randomized Trial of Intravenous Amino Acids for Kidney Protection.

Name: Αlpha¹ Rigor Record — A Randomized Trial of Intravenous Amino Acids for Kidney Protection.
Item: A Randomized Trial of Intravenous Amino Acids for Kidney Protection.
Rating: 96
Author: Αlpha¹

Landoni G, Monaco F, Ti LK, Baiardo Redaelli M, Bradic N, Comis M, Kotani Y, Brambillasca C, Garofalo E, Scandroglio AM, Viscido C, Paternoster G, Franco A, Porta S, Ferrod F, Calabrò MG, Pisano A, Vendramin I, Barucco G, Federici F, Severi L, Belletti A, Cortegiani A, Bruni A, Galbiati C, Covino A, Baryshnikova E, Giardina G, Venditto M, Kroeller D, Nakhnoukh C, Mantovani L, Silvetti S, Licheri M, Guarracino F, Lobreglio R, Di Prima AL, Fresilli S, Labanca R, Mucchetti M, Lembo R, Losiggio R, Bove T, Ranucci M, Fominskiy E, Longhini F, Zangrillo A, Bellomo R, PROTECTION Study Group

Paper source

Read full text

Embed this Rigor badge

Αlpha¹ Rigor Review — 2.75★ (Weak), 0 critical, 2 high issues for “A Randomized Trial of Intravenous Amino Acids for Kidney Protection.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

2.75 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported randomized controlled trial with strong internal validity, clear ethics documentation, and appropriate statistical methods. The main weakness is the vague data sharing statement, which lacks concrete access details. Minor copyedit issues and an overstated generalizability claim are also noted.

Both reviewers agreed on study type (interventional) and on all dimension statuses. The only divergence was minor (regulatory compliance and limitations addressed), which did not affect statuses. The statistics verification covered only 3 tests; the rest are unverified. The citation check found no retracted or missing references.

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites numerous animal and human studies supporting the biological plausibility (renal hypoperfusion, amino acids recruiting renal functional reserve). The rationale directly leads to the trial hypothesis. Limitations of prior research are implicitly addressed by the need for a large definitive trial, though not explicitly framed as addressing prior limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale linking amino acid infusion to kidney protection.

Evidence

paraphrase[Introduction, paragraph 2]

“Previous studies have shown that infusion of amino acids increases nephron plasma flow by means of decreased afferent arteriolar resistance, decreased tubuloglomerular feedback activation, and increased cortical nitric oxide synthase activity.”

direct quote[Introduction, paragraph 3]

“to test the hypothesis that intravenous amino acid therapy would lead to a lower occurrence of postoperative AKI than placebo.”